



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/570,554	12/07/2006	Willem Broekaert	1187-44	5372
28249	7590	07/28/2008	EXAMINER	
DILWORTH & BARRESE, LLP			COLLINS, CYNTHIA E	
333 EARLE OVINGTON BLVD.				
SUITE 702			ART UNIT	PAPER NUMBER
UNIONDALE, NY 11553			1638	
			MAIL DATE	DELIVERY MODE
			07/28/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)
	10/570,554	BROEKAERT ET AL.
	Examiner	Art Unit
	Cynthia Collins	1638

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 03 March 2006.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-22 and 24-31 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) _____ is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) 1-22 and 24-31 are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ . |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ . | 6) <input type="checkbox"/> Other: _____ . |

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 2-5, 7-8, 11, 13-14 and 20-22, drawn to a method comprising increasing expression, activities or levels in a plant of an *Arabidopsis thaliana* CDK;B1;1 plant B-type CDK protein.

Group II, claim(s) 2-5, 7-8, 12-14 and 20-22, drawn to a method comprising increasing expression, activities or levels in a plant of an *Arabidopsis thaliana* CDK;B1;2 plant B-type CDK protein.

Group III, claim(s) 2-6, 9, 12-15 and 20-22, drawn to a method comprising increasing expression, activities or levels in a plant of an *Arabidopsis thaliana* CDK;B2;2 plant B-type CDK protein.

Group IV, claim(s) 2-4, 10, 13-14 and 20-22, drawn to a method comprising increasing expression, activities or levels in a plant of an *Arabidopsis thaliana* plant B-type CDK protein variant (mutant).

Group V, claim(s) 2-3, 13-14 and 20-22, drawn to a method comprising increasing expression, activities or levels in a plant of an algal B-type CDK protein.

Group VI, claim(s) 2-3, 13-14 and 20-22, drawn to a method comprising increasing expression, activities or levels in a plant of a fungal B-type CDK protein.

Group VII, claim(s) 16-17 and 19, drawn to a construct according to claim 16 wherein the nucleic acid of (a) is a CDK B1;2.

Group VIII, claim(s) 16 and 18-19, drawn to a construct according to claim 16 wherein the nucleic acid of (a) is a CDK B2;2.

Group IX, claim(s) 24, drawn to a composition comprising a protein represented by SEQ ID NO:2.

Group X, claim(s) 24, drawn to a composition comprising a protein represented by SEQ ID NO:4.

Group XI, claim(s) 24, drawn to a composition comprising a protein represented by SEQ ID NO:6.

Group XII, claim(s) 25 and 27, drawn to a first screening method.

Group XIII, claim(s) 26-27, drawn to a second screening method.

Groups XIV-XVIII, claim(s) 30, drawn to an isolated nucleic acid molecule encoding a CDK mutant. Group XIV is drawn to an isolated nucleic acid molecule encoding a CDK mutant represented by SEQ ID NO:9, Group XV is drawn to an isolated nucleic acid molecule encoding a CDK mutant represented by SEQ ID NO:10, Group XVI is drawn to an isolated nucleic acid molecule encoding a CDK mutant represented by SEQ ID NO:11, Group XVII is drawn to an isolated nucleic acid molecule encoding a CDK mutant represented by SEQ ID NO:12, Group XVIII is drawn to an isolated nucleic acid molecule encoding a CDK mutant represented by SEQ ID NO:13.

Groups XIX-XXIII, claim(s) 28-29 and 31, drawn to a CDK mutant. Group XIX is drawn to a CDK mutant represented by SEQ ID NO:9, Group XX is drawn to a CDK mutant represented by SEQ ID NO:10, Group XXI is drawn to a CDK mutant represented by SEQ ID NO:11, Group XXII is drawn to a CDK mutant represented by SEQ ID NO:12, Group XXIII is drawn to a CDK mutant represented by SEQ ID NO:13.

Claim 1 link(s) inventions I-VI. The restriction requirement between the linked inventions is **subject to** the nonallowance of the linking claim(s), claim 1. Upon the indication of allowability of the linking claim(s), the restriction requirement as to the linked inventions **shall** be withdrawn and any claim(s) depending from or otherwise requiring all the limitations of the allowable linking claim(s) will be rejoined and fully examined for patentability in accordance with 37 CFR 1.104 **Claims that require all the limitations of an allowable linking claim** will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

Applicant(s) are advised that if any claim presented in a continuation or divisional application is anticipated by, or includes all the limitations of, the allowable linking claim, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. *In re Ziegler*, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

The inventions listed as Groups I-XXIII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The technical feature linking the inventions of Groups I-XXIII is a B-type CDK polypeptide or a nucleic acid encoding a B-type CDK polypeptide. However, a B-type CDK polypeptide or a nucleic acid encoding a B-type CDK polypeptide is obvious or anticipated over WO 98/41642 (INZE D. et al., 24 September 1998, Applicant's Search Report), and therefore does not constitute a special technical feature as defined by PCT Rule 13.2, because it does not define a contribution over the prior art.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

The examiner has required restriction between product and process claims (between Group VI process and Groups XIV-XVIII products; between Groups XII-XIII processes and Groups XIX-XXIII products). Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder. All claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.** Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Cynthia

Art Unit: 1638

Collins whose telephone number is (571) 272-0794. The examiner can normally be reached on Monday-Friday 8:45 AM -5:15 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anne Marie Grunberg can be reached on (571) 272-0975. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Cynthia Collins/
Primary Examiner, Art Unit 1638

CC